MAIA Biotechnology, Inc. (MAIA)
ASE · Healthcare · Biotechnology
$1.20
-3.23%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$73.0M
Shares Outstanding
60.8M
Exchange
ASE
Currency
USD
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.2M | -9.4M | -4.0M | -6.7M |
| Net Income | -5.3M | -8.9M | -3.6M | -6.4M |
| Diluted EPS | $-0.18 | $-0.27 | $nan | $-0.14 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -15.9M | -20.0M | -16.9M | -23.9M |
| Net Income | -15.8M | -19.8M | -23.3M | -22.4M |
| Diluted EPS | $-1.75 | $-1.49 | $-1.05 | $-0.70 |